Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$85.00 -18.44 (-17.83%)

(As of 12/20/2024 05:45 PM ET)

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
1

Buy
6

Based on 7 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for NVO.

Consensus Price Target

$150.40
76.94% Upside

According to the 7 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $150.40. The highest price target for NVO is $160.00, while the lowest price target for NVO is $120.00. The average price target represents a forecasted upside of 76.94% from the current price of $85.00.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$150.40	$144.50	$145.17	$115.00
Forecasted Upside	76.94% Upside	40.61% Upside	13.85% Upside	11.95% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	76.94% Upside	25,828.93% Upside	14.52% Upside
News Sentiment Rating	Neutral News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/2/2024	BNP Paribas 3 of 5 stars	R. Parkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
11/6/2024	Cantor Fitzgerald 4 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+49.39%
10/17/2024	BMO Capital Markets 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$160.00 ➝ $156.00	+31.57%
6/10/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$156.00	+17.58%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$120.00	+13.75%
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
1/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:34 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Recent institutional interest has surged, with Wellington Management Group acquiring approximately $42 million in shares, indicating strong confidence in the company's future performance.
The stock is currently priced at $108.70, which is below its one-year high of $148.15, suggesting potential for price appreciation as the market recovers.
Analysts have recently upgraded their ratings, with Cantor Fitzgerald setting a price target of $160.00, reflecting optimism about the company's growth prospects.
Novo Nordisk has a solid market capitalization of $487.79 billion, which provides stability and resources for continued innovation and expansion in the diabetes and obesity treatment markets.
The company maintains a low debt-to-equity ratio of 0.43, indicating a strong balance sheet and lower financial risk, which is attractive for long-term investors.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

The stock has recently experienced a decline of 2.7%, which may indicate short-term volatility and investor uncertainty.
Despite positive analyst ratings, one research analyst has issued a hold rating, suggesting that not all market participants are convinced of the stock's immediate upside.
With a price-to-earnings (P/E) ratio of 36.15, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
The company's current ratio of 0.94 is below 1, indicating potential liquidity issues, which could affect its ability to meet short-term obligations.
Recent trading volumes have been lower than average, which may suggest reduced investor interest and could lead to increased price volatility.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $150.40, with a high forecast of $160.00 and a low forecast of $120.00.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There is currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVO shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 76.94% based on their 12-month stock forecasts.
: Over the previous 90 days, Novo Nordisk A/S's stock had 1 upgrade by analysts.
: Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, BNP Paribas, and Cantor Fitzgerald in the past 90 days.
: Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating for Novo Nordisk A/S is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NYSE:NVO) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target